Drug Store News - Digesting an acquisition: Patrick Hennig, Boehringer Ingelheim
Tuesday, January 6th, 2009 Following the announcement that Johnson & Johnson would acquire Pfizer Consumer Healthcare, Boehringer Ingelheim Pharmaceuticals entered into an agreement with Johnson & Johnson and Pfizer to acquire the U.S. rights to the over-the-counter Zantac product line for $509.5 million in cash.
Drug Store News caught up with Boehringer Ingelheim’s Patrick Hennig for his thoughts on Boehringer’s digestive p…
